Nuked: Idenix has meltdown over partial hold on HCV drug
This article was originally published in Scrip
Executive Summary
Shares of Idenix Pharmaceuticals plunged as low as 35% on 16 August after the US FDA slapped a partial hold on the firm's clinical program for IDX184, an experimental nucleotide polymerase inhibitor under investigation to treat hepatitis C virus (HCV).